Griffen Securities Positive on ZIOPHARM's (ZIOP) Latest Membrane-Bound IL-15 Data; Affirms at 'Buy'
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Ziopharm Oncology (ZIOP) Announces Presentation of Ad-RTS-hIL-12 + Veledimex Data at 21st ASM of SNO
November 17, 2016 7:08 AM ESTZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced the presentation of both clinical and nonclinical data for Ad-RTS-hIL-12 + orally-administered veledimex for recurrent brain cancer at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) held November 17-20, 2016 in Scottsdale, Arizona. Ad-RTS-hIL-12 + veledimex is a novel viral gene therapy candidate utilizing the proprietary RheoSwitch Therapeutic System® (RTS®) technology for the controlled expression of interleukin 12 (IL-12), a critical protein for stimulating a vigorous immune response against cancers.
In a poster presentation titled Phase 1 study of intra-tumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex is well... More